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Skin is a fundamental component of our host defense system that provides a dynamic
physical and chemical barrier against pathogen invasion and environmental insults.
Cutaneous barrier function is mediated by complex interactions between structural
cells such as keratinocytes and diverse lineages of immune cells. In contrast to the
protective role of these intercellular interactions, uncontrolled immune activation can lead
to keratinocyte dysfunction and psoriasis, a chronic inflammatory disease affecting 2%
of the global population. Despite some differences between human and murine skin,
animal models of psoriasiform inflammation have greatly informed clinical approaches
to disease. These studies have helped to identify the interleukin (IL)-23-IL-17 axis
as a central cytokine network that drives disease. In addition, they have led to the
recent description of long-lived, skin-resident innate lymphocyte and lymphoid cells that
accumulate in psoriatic lesions. Although not completely defined, these populations have
both overlapping and unique functions compared to antigen-restricted αβ T lymphocytes,
the latter of which are well-known to contribute to disease pathogenesis. In this review,
we describe the diversity of innate lymphocytes and lymphoid cells found in mammalian
skin with a special focus on αβ T cells, Natural Killer T cells and Innate Lymphoid cells. In
addition, we discuss the effector functions of these unique leukocyte subsets and how
each may contribute to different stages of psoriasis. A more complete understanding of
these cell types that bridge the innate and adaptive immune system will hopefully lead to
more targeted therapies that mitigate or prevent disease progression.
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INTRODUCTION
The skin is the largest barrier organ. The most superficial layer of mammalian skin consists of an
avascular, stratified epithelial layer that provides a physical and chemical barrier to environmental
insults, is responsible for hair formation and supports a diverse commensal microbial community
that promotes colonization resistance to invasive pathogens. Underlying the epidermis is the
dermis composed of a fibroblast network providing structure for a complex neurovascular system
that regulates heat transfer, pain sensation, and host defense (1). The epidermis and dermis harbor
unique leukocyte subsets that are not only central to cutaneous immunity, but also contribute
to basic skin physiology including wound healing, hair follicle cycling, and lipid production by
sebaceous glands. Given the intimate relationship between immune-structural cell interactions,
it stands to reason that aberrant communication within this compartment can lead to altered
host defense mechanisms and/or dysregulated skin inflammation and disease. One of the most
common cutaneous inflammatory diseases is psoriasis. Affecting between 2 and 5% of the adult
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FIGURE 1 | γδ T cells and ILCs in psoriatic skin. Diverse subsets of γδ T cells colonize the skin. Under homeostatic conditions, the mouse epidermis contains
dendritic epidermal T cells, which are a monoclonal population of Vγ5+ cells. The dermis contains Vγ4+ and Vγ6+ γδ T cells enriched for expression of IL-23R, CCR6,
and IL-7R. In mouse models of psoriasiform inflammation, activated keratinocytes produce chemokines such as CCL2 and CCL20, which subsequently recruit dermal
γδ T cells to the epidermis. Among these γδ T cells, there is a subgroup that express the transcriptional factor RORγt, that are capable of producing IL-17 and IL22
upon IL-1 and IL-23 stimulation. Both mouse and human studies have shown that, upon cytokine stimulation, dermal-derived γδ T cells secrete IL-17 and IL-22 that
drives keratinocyte hyperplasia, neutrophil recruitment and disease progression. ILCs are also present in the healthy skin. They are divided into three groups based on
transcription factor expression and effector functions. Under steady-state conditions, ILC2 are the largest population. ILC3 are currently thought to be the dominant
population that contribute to disease progression. In human skin lesions, NKp44+ ILC3s are able to produce IL-22 and IL-17 that exacerbate disease progression.
population in developed countries, psoriasiform inflammation
varies in severity but is most commonly characterized by red,
scaly plaques across the surface of the body in a form referred
to as psoriasis vulgaris. Although the etiology of psoriasis has
not been identified, both environmental and genetic factors have
been shown to contribute to incidence and severity of disease (1–
3). Importantly, psoriasis is associated with comorbidities such
as atherosclerosis and metabolic syndrome suggesting systemic
dysregulation of the immune response in these patients providing
further motivation for understanding disease pathogenesis (1,
4). Despite some differences between human and rodent
skin, animal models of “psoriasiform” inflammation have been
instrumental in identifying the immunological mechanisms
underlying psoriasis development. For example, the models
described in more detail below have helped to determine the
interleukin (IL)-23/IL-17 axis as central to disease progression
(1, 5). The essential role of these cytokines has been validated
by the clinical efficacy of humanized monoclonal antibodies
targeting TNFα, IL-23, IL-17A, and the IL-17 receptor (6, 7).
However, these treatment approaches have limitations. First,
they are not curative; symptoms reappear upon cessation of
treatment. Thus, biologics must be given throughout the patient’s
lifetime. Second, the IL-23/IL-17 immune axis plays an important
role in protection against cutaneous pathogens such as Candida
and pathobiotic spp. of Staphylococcus areus (8, 9), thus raising
questions about the long-term use of these treatments regarding
susceptibility to infection. Furthermore, these biologics do not
specifically target the skin and may compromise host defense
at other barrier sites such as the intestine. Therefore, further
investigation into the initiating factors that drive psoriatic disease
will not only enrich our knowledge of skin biology in general, but
lead to more targeted, tissue-specific treatments for this chronic
inflammatory disease.
The recent discovery of immune cell subsets that are resident
to the skin such as γδ T cells and innate lymphoid cells
(ILCs) has prompted a growing interest in how these and other
better known cell types that blur the separation between the
innate and adaptive immune system such as Natural Killer (NK)
cells and NKT cells contribute to psoriasiform inflammation.
Indeed, these cells serve as acute sensors of infection and tissue
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injury without the need for specific recognition of antigen.
While these properties have likely evolved to respond rapidly
to tissue changes, their non-specific activation requirements
leave them susceptible to hyperreactive responses against
innocuous stimuli. In this review, we describe the diversity
of innate lymphocyte lineages present in the skin and our
current understanding of how each subset contributes to the
pathogenesis of psoriatic disease.
THE CUTANEOUS γδ T CELL
COMPARTMENT
Of the innate T lymphocytes in the skin, γδ T cells,
defined by expression of gamma (γ) and delta (δ) TCR
subunits, are the most studied. Their innate classification
comes from two main characteristics: first, the repertoire
of γ and δ chains possess less diversity than their more
classical αβ TCR counterparts. Second, γδ T cells do not
require TCR engagement in order to expand and exert their
effector functions. Rather, cytokines alone are sufficient to
endow γδ T cells with cytotoxic and cytokine-producing
ability (10).
In mice, γδ T are usually distinguished based on the γ
chain expression. It is worth mentioning that two nomenclatures
are often used but rarely specified in the literature, namely
the Heilig and Tonegawa vs. the Garman classification. In this
review, we will use the Heilig and Tonegawa nomenclature only,
which includes the Vγ1–Vγ7 subtypes (11). Each subtype has a
propensity to localize to specific organs as well as exert unique
effector functions. Their development and migration to the
epithelial tissues starts during fetal life (12–14) with consecutive
waves associated with different γδ T subsets migrating from
the thymus to their specific tissue (10, 15). From day E13, the
Vγ5 subtype is produced in the thymus and migrates to the
epidermis (Figure 1). Vγ5 γδ T cell development is exclusively
fetal and occurs only in mice. These cells are called dendritic
epithelial T cells (DETC) due to their morphology, are non-
migratory and are maintained by self-renewal (16, 17). As DETC
seem to be most relevant for maintaining skin homeostasis and
wound repair and have been reviewed extensively elsewhere,
we will not be discussing this subset further. On the other
hand, Vγ4 and Vγ6 subtypes constitute the dermal γδ T cell
compartment (Figure 1). Unlike DETCS, dermal γδ T cells are
motile with Vγ6+ cells seeding the dermis during fetal life
and Vγ4+ cell recruitment limited to the first days of life
(18). Accordingly, the dermal γδ T cell compartment can be
replenished after irradiation, but only if neonatal thymocytes are
transferred (19).
Vγ usage is also associated with a specific effector function
profile. In fact, γδ T cells can be largely defined based on
their expression of lineage-restricted transcription factors and
effector functions. The most prominent subsets include IFNγ
(γδ1) and IL-17 producing γδ T cells (γδ17) that rely on the
transcription factors T-bet and RORγt, respectively, for their
differentiation (20). Interestingly, however, γδ T cell effector
functions are uniquely imprinted in the thymus where SOX13
drives γδ T cell lineage commitment and subsequent TCR
dependent and independent mechanisms that dictate effector
functions (21). For example, CD27 is a thymic determinant of γδ
T cell fate by promoting γδ1 over γδ17 cells and inducing IFNγ-
associated genes (22). Additionally, strong TCR engagement
favors IFNγ-producing γδ T development (23) while limiting
γδ17 development (24). As a result, IFNγ and IL-17-producing
γδ T subsets can be identified on the basis of CD27 and CCR6
expression, amongst other markers (22, 25). Dermal Vγ4+ and
Vγ6 + γδ T cells express several hallmarks similar to Th17
cells including RORγt, IL-7R, CCR6, and IL-23R expression
as well as ability to produce IL-17 (19, 26). They can be
stimulated by IL-23, which leads to their expansion and IL-
17 production (26) (Figure 1). Dermal γδ T cells have been
associated with immunosurveillance functions. In the context
of mycobacterial infections, they have been shown to be the
dominant source of IL-17 and their absence was correlated
with diminished immune response to BCG immunization
(27). Furthermore, IL-17 production by dermal γδ T can be
stimulated by various microbe-derived products (26), further
emphasizing their immune sentinel role. As Vγ6+ cells are
rarely found in secondary lymphoid organs, MacKenzie et al.
suggested that this subset might have specifically evolved for
immunosurveillance of non-lymphoid tissues while the more
migratory, lymphoid organ-skewed Vγ4 subset might serve
as a pool that is rapidly mobilized to barrier sites following
challenge (28).
In humans, γδ T cells are usually distinguished based
on δ chain expression including Vδ1, Vδ2, and Vδ3 (i.e.,
Vδ1-Vδ2-) subtypes. Vδ1 cells seed barrier tissues while Vδ2
and Vδ3 are observed in the blood of healthy patients (29).
Similar to murine γδ T cells, human γδ T cells are potent
cytokine-producing cells, but the regulatory mechanisms are
less understood. Unlike murine γδ T cells, human γδ T cells
are more dependent on TCR engagement for activation and
appear to produce a greater diversity of effector cytokines. For
example, human γδ17 cell differentiation, which likely occurs
in the periphery since they are absent from the human mature
thymus (30), requires IL-23 and TCR activation. Furthermore,
Vγ9Vδ2 cells that represent the majority of the Vδ2 subset,
exhibit remarkable heterogeneity in term of surface markers
and cytokine production. These plastic cells are able to produce
IFNγ, IL-4, or IL-17, which contrasts with murine γδ T cell
commitment (31).
As opposed to mice, human γδ T cells are rare in the
skin with Vδ1-expressing cells being the dominant subtype
observed in healthy skin, mainly in the dermis. With the
help of αβ T cells (16), Vδ1 seem to recapitulate the role
of DETC given that they present a restricted repertoire (32),
can be observed in the epidermis, produce keratinocyte growth
factors and exert anti-tumor activity (31, 33). Vδ1+ cells are
also usually associated with IFNγ production and a cytotoxic
profile (34). Notably, human dermis-derived γδ T cells have
been shown to produce IL-17A. In fact, Cai et al. found IL-17-
producing γδ T cells to be enriched in psoriatic skin lesions.
However, the full repertoire of cutaneous γδ T cells has yet to be
investigated (26).
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γδ T Cells Are Major Contributors to
Murine Psoriasiform Inflammation and
Implicated in Human Disease
Two mouse models of cutaneous inflammation are most
commonly used to study the mechanisms underlying
psoriasiform inflammation. The imiquimod (IMQ) model
that consists of topically applying a TLR7/8 agonist emulsified in
a cream or intradermal injection of recombinant IL-23 (5, 35).
Both approaches lead to epidermal hyperplasia, parakeratosis,
and expansion of rete ridges, all features of psoriasiform
inflammation (36). These preclinical models have been shown
to depend on the presence of IL-17 for fulminant inflammation
and motivated clinical trials the development of neutralizing
antibodies targeting IL-23, IL-17A, or IL-17RA (the receptor
for both IL-17A and IL-17F) (5–7, 26). The incredible clinical
success of these biologics has validated these models and led
to further investigation into the cell types driving IMQ and
IL-23-induced inflammation (6, 7). Importantly, both models
revealed decreased inflammation and psoriasiform symptoms
inflammation in mice genetically lacking γδ T cells (TCRδ−/−)
compared to mice deficient in αβ T cells (TCRα−/−) mice
(26, 37). Importantly, TCRδ−/− mice reconstituted with Vγ4
and Vγ6 subpopulations restored disease susceptibility (18).
Similarly, selective depletion of Vγ6+ or Vγ4+ γδ T cells using
antibody-mediated or genetic depletion approaches indicate
that both subsets are necessary and sufficient for IMQ-induced
inflammation (38, 39). Interestingly, Vγ4+ γδ T cells have
been shown to have memory-like capacity. Indeed, two papers
have demonstrated that this γδ T cell subset persists in the
skin after termination of IMQ treatment and exhibits classical
features of memory cells upon secondary IMQ challenge (i.e.,
a more rapid response with greater magnitude) in the same
area or even distant sites (40, 41). Ramirez-Valle et al. further
demonstrated that the migration and recruitment to distant
sites was mediated via CCR2 signaling (41). They showed
that IMQ-activated Vγ4+ T cells expressed less CCR6 than
unchallenged γδ T cells and that the former subset demonstrated
increased responsiveness to IL-1. Downregulation of CCR6
was unexpected as it was previously shown that both models
of psoriasis induce CCL20 (42), the chemokine recognized by
CCR6, and that a CCL20/CCR6 axis was essential for disease
progression (38, 43) (Figure 1). Induction of CCL20 leads
to dermal IL-17+γδ T cell recruitment into the epidermis,
exacerbating inflammation. Accordingly, an anti-CCL20
antibody treatment reduced IL-23-induced inflammation by
decreasing the γδ T trafficking into the epidermis (42). In
the latter study, the source of chemokine secretion was not
identified but it has been demonstrated that IL-1β can stimulate
keratinocyte production of CCL2 and CCL20, which might
impact γδ T cell recruitment (18). In addition, activated dermal
γδ T cells increase expression of X-linked IL-1 receptor accessory
protein-like 1 (IL1RAPL1) which promotes a feedforward
system inducing more IL-17 production by these cells. IL-38, a
cytokine of the IL-1 family secreted by keratinocytes at steady
state, is able to restrict γδ T cell activity by inhibiting IL1RAPL1
on the surface of γδ T cells (44). Accordingly, the levels of
TABLE 1 | Cytokines produced by innate immune cells during psoriasis.
Cytokine Cell types References
IL-17A γδT cell, ILC3, NK cell (18, 26, 37, 38, 46–49)
IL-22 γδT cell, ILC3, NK cell (37, 47, 50)
IL-25 (IL-17E) γδT cell (51)
IFNγ NK and NKT cell (52–55)
TNFα NK and NKT cell (53)
IL-38 secreted by the keratinocytes is decreased in psoriatic
lesions as well as in mouse skin following IMQ treatment
(44, 45). These results underline the loop that exacerbates
psoriasis, where inflammation induces keratinocytes secretion
of chemokines, which in turn triggers γδ T cell recruitment. The
pro-inflammatory environment leads to cytokine production by
γδ T cells, which promotes keratinocyte hyperproliferation and
epidermal thickening.
Although γδ T cells are capable of cytotoxic activity, their
potent cytokine production seems to play a dominant role in
psoriasiform inflammation (Table 1). In the IMQ model, both
IL-17 and IL-22 production by RORγt + γδ T cells, Vγ4+ cells
in particular, is greatly increased (37) (Figure 1). Consistent with
these results, IL-17R deficient mice showed reduced and delayed
signs of psoriasiform inflammation such as ear thickness and
erythema after IMQ treatment (56). However, disease was not
completely abolished in IL-17R deficient mice and increased
levels of TNFα, IL-6, and IL-22 as well as IL-17-producing cells
were observed in the skin. This demonstrates the importance
of IL-17 signaling for psoriasiform inflammation, but also
suggests an alternative pathway for IMQ-induced inflammation.
Similarly, IMQ-induced inflammation was strongly reduced in
mice with a keratinocyte-specific deletion of the IL-17 receptor
(57). In another study using the IMQ model, the main producer
of IL-22 was also γδ T cells. However, in Rag-deficient mice that
lack mature T and B cells, levels of IL-22 in response to IMQ
remained elevated suggesting an alternative source of cutaneous
IL-22 (50). Although it was shown that, in addition to IL-17,
IL-22 is required for IL-23 induced inflammation, the failure of
clinical trials using anti-IL-22 antibodies have kept the focus on
the effector functions of IL-17 and its associated family members.
In fact, a recent report showed that IL-17E (better known as
IL-25) signaling via IL-17RB also plays an important role in
IMQ-induced psoriasiform inflammation (51). This work was
recently followed up by studies demonstrating that IL-17A can
signal via an alternative receptor, IL-17RD, to drive psoriasiform
inflammation (58). To conclude, γδT cells aremajor contributors
to murine psoriasiform inflammation via the production of IL-
17 and IL-22 (Figure 1, Table 1). The Vγ4 subtype is particularly
implicated in the disease due to its quick cytokine response,
migration capacities and long-lasting memory capacity.
Such as in mice, γδ T cells are expanded in human psoriatic
skin and produce IL-17A (26) (Table 1). A population of
Vγ9Vδ2+ cells that express IL-17A, IFNγ, TNFα and CCR6
has been specifically observed in human psoriatic lesions (59).
These cells were able to activate keratinocytes and stimulate
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chemokine, cytokine and defensin production. Laggner et al.
also showed that Vγ9Vδ2+ cells were increased in psoriatic skin
compared to healthy skin and, even more, increased in lesional
skin compared to non-lesional skin of the same patients (59). In
addition, Vγ9Vδ2+ cells were reduced in psoriatic patient blood.
Finally, they showed a negative correlation between blood levels
of Vγ9Vδ2+ cells and psoriasis severity. These results suggest that
the Vγ9Vδ2+ population is recruited from the peripheral blood
to the skin where they activate keratinocytes and contribute to
psoriasis development. On the other hand, it has been recently
shown that the majority of IL-17A producing T cells observed in
human psoriatic lesions are oligoclonal αβ T cells and not γδ T
cells (60). Furthermore, mast cells have been shown to produce
IL-17A and IL-22 in human psoriatic plaques (61). The diverse
subsets previously found to be expressing and/or producing IL-
17 cytokines in human psoriasis and disparate results between
groups continues to fuel a controversy over the most relevant
cytokine-producing cells for psoriatic disease development and
progression. Longitudinal studies using large, diverse patient
cohorts may help reconcile these differences.
THE INNATE LYMPHOID CELL SKIN
POPULATION
ILCs are bone marrow-derived tissue-resident lymphocytes that,
although arising from common lymphoid progenitors, do not
express rearranged antigen-specific receptors. ILC nomenclature
is largely analogous to CD4+ T helper effector cell subsets:
ILC1s express the transcription factor T-bet and secrete IFNγ,
ILC2s express GATA3 and produce the Th2 cytokines IL-5 and
IL-13 and ILC3s express RORγt and secrete IL-17 and IL-22.
Although ILCs are thought to be largely tissue-resident cells (62),
ILCs have been detected in the circulation that express high
levels of cutaneous leukocyte-associated antigen (CLA), a skin
homing marker (63). In both mice and humans, all three groups
of ILCs have been observed in the skin with ILC2s being the
largest population (63–65). Furthermore, a study examining the
cutaneous ILC population in mice showed that different layers
of the skin are populated differentially by ILCs: the epidermis is
mainly populated by ILC3s, the subcutaneous layer is populated
by ILC2s and the dermis contains both ILC2s and ILC3s (66)
(Figure 1). However, the signals that result in the differential
homing of ILCs in the skin and whether this is representative
of human ILC populations is not completely understood. ILC1s,
although present in the skin, are a rare population with unknown
functions. Although sharing several features with natural killer
(NK) cells, ILC1s do not exert cytotoxic activity—lack perforin
and granzyme expression—and do not express traditional NK cell
antigens such as CD56, CD16, or CD94. However, the cytokine
profile of ILC1s, most notably IFNγ, resembles NK cells and has
been shown to play a role in the protection against intracellular
pathogens (62, 67, 68). As ILC1s are thought to contribute to
Crohn’s disease and inflammation in a mouse model of colitis
(69, 70), they could potentially play similar roles in the skin both
in terms of protection as well as autoimmune-like pathology,
however this has not been thoroughly investigated. ILC2s on the
other hand are much more common in the skin and are thought
to play a role in maintaining skin homeostasis. For example,
ILC2s have been shown to promote wound healing in the skin
through the production of IL-13 (71, 72). Skin-resident ILC2s can
also produce high levels of amphiregulin, a molecule regulating
wound healing (73). In dermatitis, amphiregulin has been shown
to play a role in wound healing by acting as an epidermal growth
factor receptor (EGFR) ligand (74). However, other evidence
indicates the involvement of ILC2s in allergic-type or type 2
inflammation of the skin, namely atopic dermatitis likely through
dysregulated production of type 2 cytokines such as IL-5 and IL-
13 (73, 75, 76). Lastly, ILC3s are one of the subtypes of immune
cells in the skin capable of producing IL-17A and IL-22 and are
therefore of specific interest when discussing psoriasis (Figure 1).
ILC3s Are Observed in Human Psoriatic
Skin and Correlate With Disease Severity
While ILC3s seem to play a role in the development and
maintenance of psoriasis, the role of ILC1 and 2 subsets is a
matter of debate (Figure 1). Some groups found a reduction in
ILC2 numbers in psoriatic patients (64) while others saw no
difference in frequencies. Notably, different methods of tissue
processing from skin biopsies in these studies may explain the
differences (63–65). Given that ILC2s are known to play a role in
maintaining skin homeostasis and wound healing (71, 72), they
may also be playing a protective role during the development
of psoriasis. Second, these studies did not indicate involvement
of ILC1s (63–65). However, one group reported a significant
increase in the number of ILC1s in psoriatic skin (77); this latter
group detected the number of ILCs using imaging of whole skin
whereas the other groups performed flow cytometry which may
explain the difference. Since ILC1s in the gut seem to play a role
in inflammatory pathologies, it is possible that ILC1s may also
be paying a role in inflammatory pathologies in the skin such as
psoriasis. When looking at the cells in circulation, both healthy
individuals and psoriatic patients have a similar mean frequency
of ILCs in total peripheral blood mononuclear cells (PBMCs)
(65). However, there seems to be an overall increase of ILCs in
psoriatic skin (Figure 1). This increase in ILCs is mainly due to
an increase of ILC3s (63, 64, 77). NKp44 has been associated
with pro-inflammatory functions in ILC3s, its activation leading
to TNFα production (78). ILC3s in the skin of healthy patients
were shown to be mainly NKp44–, whereas NKp44+ ILC3s were
barely detectable in the skin and blood (63). NKp44 expression
is induced in NKp44-ILC3s upon IL-1β and IL-23 stimulation,
cytokines commonly present in psoriatic inflammation (63)
(Figure 1). In psoriasis patients, the levels of NKp44+ ILC3 but
not NKp44– ILC3s were increased in the blood, lesional, and
non-lesional skin. Furthermore, psoriasis severity as measured by
the PASI scoring system positively correlated with the number of
cutaneous NKp44+ ILC3s (63–65). These data suggest that the
amount of NKp44+ ILC3s in the blood or the skin can potentially
be used as a biomarker for disease severity. Furthermore, ILCs
in psoriatic skin were seen to be in close proximity to T cells,
suggesting a crosstalk between ILCs and T cells during the
development of psoriasis (77). Given the innate features of ILC3s
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and their largely tissue-resident nature, these cells may contribute
to the initiation of psoriatic inflammation. Indeed, ILC3s alone
were able to induce psoriasis in a human skin xenotransplant
mouse model to a degree similar to αβ T cells (79). Furthermore,
patients with psoriatic arthritis, a disorder with similar features of
psoriasis but with joint involvement, also had an increased ILC3:
ILC2 ratio (80).
As mentioned above, IL-17 producing γδ T cells have been
shown to be important drivers of IMQ-induced inflammation
(81). However, it has been shown that Rag-deficient mice are
still susceptible to psoriasiform inflammation via IMQ (37,
43), indicating that cells other than T cells play a role in
the pathogenesis. Using Rag1/IL-2R deficient mice lacking T
cells and ILC, Pantelyushin et al. showed that RORγT+ γδ T
cells and RORγt+ ILC contribute to IMQ-induced psoriasiform
inflammation (37). Furthermore, anti-TNFα or TNFα inhibitor
treatment has been demonstrated to be a very effective treatment
for psoriasis (82). TNFα plays a role in psoriasis development
by synergizing with IL-23 to induce IL-17 producing cells,
including ILC3s (46). Individuals undergoing successful anti-
TNFα (adalimumab) treatment for psoriasis had a reduction
in the number of pathogenic NKp44+ ILC3s and an increase
in NKp44– ILC3s in the circulation (65), suggesting that a
major role of TNFα in the pathogenesis of psoriasis includes
potentiating pathogenic ILC3s. However, it was elegantly
demonstrated that γδ17 were non-redundant effector cells in
murine skin pathology (81). Indeed, when γδ17 cells were deleted
from birth, they were replaced by IL-17 producing ILC3s that
promoted IMQ-induced inflammation. However, acute depletion
of γδ17 cells did not lead to ILC3 accumulation and mice
remained resistant to psoriasiform inflammation. In summary,
ILC2s appear dominant in healthy skin whereas NKp44+ ILC3s
are the major ILC subset associated with psoriatic disease.
Although ILC3s and γδ17 cells may play overlapping roles in
murine models of psoriasis, more studies are needed to discern
their relative contributions to human disease.
CUTANEOUS NK AND NKT CELLS
Natural Killer (NK) cells are a group of innate immune cells with
both cytotoxic and cytokine producing effector functions and
have been recently classified as one of two ILC1 subsets (83, 84).
Through germ-line encoded activating and inhibitory receptors,
NK cells can respond quickly following activation, releasing
pro-inflammatory cytokines particularly IFNγ, chemokines, or
specialized cytotoxic granules to infected or tumor cells (85). In
human and mice, there are two distinct populations of NK cells,
circulating NK cells (cNK, CD49a+CD103− or CD56dimCD16+
in human and CD49a−DX5+ in mice) and tissue-resident
NK cells (trNK, CD49a−CD103+, or CD56brightCD16− in
human and CD49a+DX5− in mice) (Figure 2); both can induce
cytotoxicity and produce cytokines (86–89). Murine skin is
composed of both trNK cells and cNK cells (87) (Figure 2).
However, the cNK and trNK cells do not share the same
development pathways. cNK cells are derived from the bone
marrow, continue their maturation in the thymus and then
the spleen, tonsils and lymph nodes (90, 91). In mice, the
transcription factors T-bet and Eomes are required for the
maturation of cNK cells (92). In humans, both T-bet and Eomes
are co-expressed in mature cNK cells (93). T-bet is expressed
at lower levels in cytokine-producing CD56bright(CD56hiCD16−)
NK cells than the highly cytotoxic CD56dim (CD56loCD16+)
NK cells, while CD56bright NK cells have higher frequency of
Eomes+ cells than CD56dim NK cells (93), indicating that there
is a gradual loss of Eomes expression during the development of
CD56bright cells to T-bethiEomes+ CD56dim cells. trNK cells were
first discovered in the murine liver, strictly require T-bet, Hobit
and PLZF for their development, however do not express Eomes
(87, 89). Murine liver trNK cells are capable of degranulation
and produce similar IFNγ levels to cNK cells. However, both
the liver IFNγ+ and degranulating trNK cells produce TNFα,
which is rarely seen among responding cNK cells (87). Unlike
mouse trNK cells, human liver trNK cells have high Eomes
expression rather than T-bet (94). Of note, the features and
developmental pathways of trNK cells differ from one organ
to another. In the murine gut and dermis, the development
of NKp46+CD3− trNK cells is reported to be dependent on
the transcriptional factor RORγt and RORγt+ trNK cells are
capable of producing IL-22 (95). The origin of skin trNK cells is
unclear, but murine studies show that skin trNK cells share some
features with liver trNK cells, in terms of phenotype, function
and developmental requirements. They are CD49a+DX5− with
no Eomes expression, and their development is dependent on IL-
15 and IL-15R. Human CD56brightCD16−NK cells are present
in the dermis at steady state and disease conditions such as
psoriasis, while CD56+CD16+ cNK cells are rare (52, 96, 97).
These CD56brightCD16− dermal NK cells lack perforin and
NKG2D expression but are capable of lysing melanoma cells after
activation in vitro (97). Recently, studies have found IL-17 and IL-
22 producing NK cells in both humans and mice, which indicates
the potential for NK cell participation in the development of
psoriasis (47–49).
Natural Killer T (NKT) cells are present in both human
and mouse skin (Figure 2). However, the composition of NKT
cells is not well-defined. In human allergic contact dermatitis,
for example, NKT cells range from 1.72 to 33% of the T
lymphocyte infiltrate and in human atopic dermatitis patients,
the proportion of NKT cells in CD3+ T cells is ∼5% (98, 99).
In murine skin, they compose ∼0.03% of total healthy skin cells
and ∼0.6% of total hyperplastic skin cells (100). NKT cells are
a unique hybrid between αβ T cells and NK cells as they co-
express an αβ TCR and NK cell lineage markers. NKT cells
are divided into four categories with type 1 (referred to as
invariant NKT cells) being the vast majority (101). Compared
to conventional T cells, they express a semi-invariant TCR α
chain (Vα14-Jα18 in mice and Vα24-Jα18 in human), which
allows specific recognition of glycolipids presented on an atypical
MHC Class I molecule, CD1 (102–104). α-galactosylceramide
(α-GalCer), a compound derived from marine sponges, has a
strong CD1d binding affinity and is a potent stimulant for iNKT
cells. Potential endogenous ligands of NKT cells were previously
believed to be glycosphingolipids (GSLs) and phospholipids that
are derived from bacterial, plant, protozoan, and mammalian
Frontiers in Immunology | www.frontiersin.org 6 February 2020 | Volume 11 | Article 242
Polese et al. Innate Lymphocytes in Psoriasis
FIGURE 2 | NK and NKT cells in psoriatic skin. NK and NKT cells are innate immune cells that have cytokine-producing and cytotoxic functions. They both reside in
the dermis. The NK cells can be divided into two groups, namely cNK and trNK cells, based on the receptors CD49a and DX5. Unlike NK cells, NKT cells also express
an antigen-specific TCR that recognizes glycolipid through CD1 presentation by antigen-presenting cells. In psoriatic skin lesions, NK and NKT cells are rare. However,
CD1d expression is reported to be elevated in keratinocytes in inflamed skin. In addition, NK and NKT cells have decreased degranulation ability, but display increased
IFNγ production. High IFNγ production can contribute to an increase in keratinocyte-derived chemokines such as CXCL10 and CCL5, and the elevated expression of
MHCI, both of which increase cell recruitment and presentation of autoantigens. In addition, NK and NKT cells produce TNFα that activate keratinocytes in an
IL-24/Stat3-dependent manner as well as indirectly enhance dermal IL-17+T cell activation by facilitating dendritic cells to produce IL-1 and IL-23.
species. However, more recent studies suggest that NKT cell
ligands are more diverse and not limited to GSLs (105, 106).
Thus, the endogenous ligands of NKT cells are still being
clarified. When stimulated with α-GalCer or its analogs, NKT
cells rapidly produce pro- and anti-inflammatory cytokines
including IFNγ, TNFα, IL-10, IL-4, IL-13, IL-17 and GM-CSF,
and participate in the regulation of infection, autoimmunity,
and tumor immunity (107). Unlike NK cells, NKT cells undergo
positive and negative selection within the thymus, but emerge
later in development than most other T cell subsets (108, 109).
During the selection process, NKT cells are only selected when
CD1 is expressed on double positive (CD4+CD8+) thymocytes,
which segregates the NKT cell (CD161 low in human and
NK1.1- in murine at this stage) from the conventional T cell
developmental pathway (110–114). The transcriptional factors
Ras, Mek, Fyn, and Ets1 are reported to participate in the
development of murine NKT cells, and the cytokine IL-15 and
its receptor IL-15R are important during NKT cell development
(115–118). After selection, the immature human CD161low or
murine NK1.1- NKT cells either stay in the thymus or migrate
to peripheral tissues, where they undergo a maturation process
with the upregulation of CD161 (human) or NK1.1 (murine)
expression (108, 109). The transcription factor T-bet was shown
to participate in the terminal maturation of NKT cells (119).
Both mouse and human NKT cells can exert cytotoxicity and
produce seemingly antagonistic IL-4 and IFNγ cytokines upon
TCR stimulation (120, 121). However, cytokine production may
be developmentally regulated as mature NKT cells produce high
levels of IFNγ while IL-4 is dominantly produced by immature
NKT cells (108, 109). Recent data showed that NKT cells can also
secrete Th17-related cytokines such as IL-17A, IL-17F, and IL-22
(107, 122, 123). A murine CD4-NK1.1- NKT cell group, which
is the precursor of CD4-NK1.1+ NKT cell, has been found to
constitutively express RORγt and IL-23R and is a major source of
IL-17+ NKT cells (107). In addition, α-GalCer-activated murine
NKT cells, that can express RORγt and IL-17, but not IFNγ or IL-
4, develop in a c-Maf dependent way. These IL-17+NKT cells are
essential for inducing neutrophil-rich airway inflammation (122).
In humans, even though RORγt+ T-betloPLZF- NKT cells are
found in the circulating PBMCs, the IL-23R expression is almost
completely absent on circulating NKT cells. These NKT cells
show poor IL-17 release after IL-23 stimulation. However, TCR
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stimulation (e.g., α-GalCer or αCD3/CD28Ab) in the presence
of IL-2, IL-23, IL-1β and TGFβ1, NKT cells successfully produce
IL-17 but not IFNβ or TNFα (123). Interestingly, there are
more IL-23R+ NKT cells in the PBMCs and joint compartment
of Spondyloarthritis patients than healthy controls, showing
an IL-17 signature (123), which suggests that NKT cells could
participate in the development of psoriasis. Although cutaneous
NKT cells are important for the anti-microbial response due
to their ability to recognize the bacterial glycolipids via CD1d
presentation (124), they may function differently in cutaneous
diseases, a result that may depend on the microbial and/or self-
antigen repertoire of the skin. It has been shown that large
numbers of NKT cells can be recruited into human skin during
contact dermatitis, producing mainly IFNγ (98, 99) however,
results in animal studies are controversial. Murine NKT cells
were previously reported to suppress this response by producing
IL-4 and IL-13 in response to CD1d-presented haptens (125),
while it was also reported that murine NKT cells enhance the
contact sensitivity reaction (126–128). Different results may be
explained by the animal model studied, which shape the NKT
cell cytokine repertoire. Studies have found decreased number
of circulating Vα24+ NK T cells in atopic dermatitis patients,
and they produce both IL-4 and IFNγ (99, 129). NKT cells were
also shown to suppress skin transplant rejection, through the
production of IL-4 (130–132). To conclude, even though the
proportion of NK and NKT cells is rare, they do participate in
cutaneous immunity through diverse effector programs.
NK and NKT Cells Are Rare in Psoriatic
Skin
The role of NK and NKT cells in psoriasis development is
not clear. Even though studies showing involvement of NK
cells in psoriasis are rare, NK cells have been shown to be
present in psoriatic skin. Human studies show that NK cells are
recruited in psoriatic plaques, particularly in the dermis (52, 133)
(Figure 2). The psoriatic lesion-isolated NK cells exhibited low
degranulation ability. However, their cytokine-producing ability
is dependent on the source of NK cells (52, 53). Ottaviani
et al. observed higher IFNγ production by NK cells isolated
from psoriatic lesions and showed that IFNγ was able to induce
keratinocyte chemokine production (such as CXCL10 and CCL5)
and MHC-I expression (52) (Figure 2, Table 1). Consistent with
the human data, mice treated with IMQ had increased NK1.1+
cells in the skin, which suggests that either NK or NKT cells
were recruited into the skin during psoriasiform inflammation
(134). Another study showed that NK cells from PBMCs of
patients with psoriasis vulgaris have reduced cytotoxicity and
lower levels of pro-inflammatory cytokines IFNγ and TNFα (53).
However, questions remain about NK cells in the context of
psoriasis. Psoriasis was initially thought to be a IFNγ related
disease but more recent studies—and the success of biologics
targeting the IL-17 pathway—indicate a more dominant role
for TNFα and IL-17 driven disease (1, 135, 136). As suggested
above, TNFα and its associated receptors have been reported to
be elevated in psoriatic lesions compared to non-lesional skin
and TNF-R is abundantly expressed by keratinocytes (137, 138).
It has been reported that TNFα signaling is involved in IL-24-
induced psoriasis like inflammation in mice (139). In addition,
both TNFα inhibitors and blocking antibodies show efficacy
in alleviating psoriatic arthritis symptoms (140). Since both
IFNγ+ and degranulating skin trNK cells produce TNFα (87),
it is possible that skin NK cells participate in the progression
of psoriasis by the production of TNFα rather than IFNγ. To
address this question, TNFα production by NK cells in the skin
of healthy control and psoriasis patients needs to be addressed.
To date, there is no direct link between IL-17 signaling and NK
cell function in psoriasis. However, NK cells have been implicated
in protection from oral and dermal Candidiasis infections that
requires IL-23 and IL-17 signaling (8, 141, 142). Whether NK
cells participate in psoriasis via IL-17 signaling needs to be further
explored. A concern about human NK cell studies is that CD56 is
routinely used as a marker for NK cells, however, CD56 is also
found on human IL-17 and IL-22-producing ILCs (47, 143, 144).
Therefore, these studies do not exclude other CD56+ ILCs in the
involvement in psoriasis.
The NKT frequency within the psoriatic lesions is very low—
<0.1%—indicating that they are an unlikely determinant of
psoriasis development (52). However, Nickoloff et al. showed
that in vitro co-culture of NKT cells with CD1d-overexpressing
keratinocytes is able to directly induce NKT production of IFNγ
and IL-13. In addition, the in vivo injection of psoriasis lesion-
derived NKT cells into the pre-psoriatic engrafted skin in SCID
mice could successfully induce psoriatic plaques (54), indicating
a potential role of NKT cells in the psoriasis progression. Of
note, the previous attempts to use IFNγ+ CD3+/CD4+ T cell
lines to induce psoriasis using this experimental approach were
unsuccessful (145). This effect may be due to increased skin-
infiltrating CD8T cells (54), which predominantly generate
IL-17 responses in human psoriasis lesions (146). This result
is consistent with a human study showing that in psoriatic
lesions, CD1d expression was highly enhanced in keratinocytes,
which may activate the NKT cells to produce more IFNγ, thus
contributing to the progression of psoriasis (55) (Figure 2).
However, as previously mentioned, IL-17, TNFα, and GM-
CSF production by NKT cells should also be also examined.
Finally, the frequency of NKT cells expressing inhibitory
receptors rather than activating receptors (CD158b+ and/or
CD94/NKG2A+) was elevated in the circulation of psoriasis
patients and correlated with disease severity (147). To conclude,
even though they are rare in psoriatic lesions, NKT might
contribute to plaque development by IFNγ production, thus
recruiting more immune cells such as IL-17 producing T cells to
exacerbate the disease progression.
CONCLUSION
γδ T, ILC, NK, and NKT cells have all been shown to
be increased in psoriasiform inflammation in humans and
mice. Consistently, evidence suggests a correlation between
disease severity and peripheral blood levels of γδ T, ILCs, and
NKT. In addition, murine models lacking γδ T and/or ILCs
demonstrated their essential role in psoriasiform inflammation
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development suggesting that NK and NKT cells likely play
a more subtle role, a finding largely supported by studies of
plaque psoriasis in humans. One fundamental characteristic of
innate cells is their ability to respond rapidly and produce
comparatively large amounts of inflammatory mediators in
the absence of cognate antigen. Consistent with these traits,
γδ T, ILCs, and NKT are all able to produce cytokines
that have established pathogenicity in psoriasis. These results
suggest that despite the relative rarity of these populations
in psoriatic lesions, they may be more amenable to non-
specific dysregulation with important consequences for disease.
Interestingly, the emerging concept of “innate memory” (148),
as implicated in γδ T cell-driven psoriasiform inflammation,
increases the complexity of these unique leukocytes and raises
new questions about their roles in complex diseases such
as psoriasis.
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